<?xml version="1.0"?><rdf:RDF xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:edm="http://www.europeana.eu/schemas/edm/" xmlns:wgs84_pos="http://www.w3.org/2003/01/geo/wgs84_pos" xmlns:foaf="http://xmlns.com/foaf/0.1/" xmlns:rdaGr2="http://rdvocab.info/ElementsGr2" xmlns:oai="http://www.openarchives.org/OAI/2.0/" xmlns:owl="http://www.w3.org/2002/07/owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:ore="http://www.openarchives.org/ore/terms/" xmlns:skos="http://www.w3.org/2004/02/skos/core#" xmlns:dcterms="http://purl.org/dc/terms/"><edm:WebResource rdf:about="http://www.dlib.si/stream/URN:NBN:SI:doc-YHPBCI2Y/d3d88875-06da-4395-9658-abc3c97c9de3/HTML"><dcterms:extent>28 KB</dcterms:extent></edm:WebResource><edm:WebResource rdf:about="http://www.dlib.si/stream/URN:NBN:SI:doc-YHPBCI2Y/5c0a31fe-1e17-4a0a-961d-8c8691f50257/PDF"><dcterms:extent>220 KB</dcterms:extent></edm:WebResource><edm:WebResource rdf:about="http://www.dlib.si/stream/URN:NBN:SI:doc-YHPBCI2Y/bd974a83-0586-46c5-951e-8071dce72e4d/TEXT"><dcterms:extent>26 KB</dcterms:extent></edm:WebResource><edm:TimeSpan rdf:about="2005-2025"><edm:begin xml:lang="en">2005</edm:begin><edm:end xml:lang="en">2025</edm:end></edm:TimeSpan><edm:ProvidedCHO rdf:about="URN:NBN:SI:doc-YHPBCI2Y"><dcterms:isPartOf rdf:resource="https://www.dlib.si/details/URN:NBN:SI:spr-8ER5ZBJN" /><dcterms:issued>2008</dcterms:issued><dc:creator>Baumgartner, Saša</dc:creator><dc:creator>Pavli, Matej</dc:creator><dc:creator>Vrečer, Franc</dc:creator><dc:format xml:lang="sl">številka:3</dc:format><dc:format xml:lang="sl">letnik:59</dc:format><dc:format xml:lang="sl">7 strani</dc:format><dc:format xml:lang="sl">str. 121-127</dc:format><dc:identifier>ISSN:0014-8229</dc:identifier><dc:identifier>COBISSID:2364273</dc:identifier><dc:identifier>URN:URN:NBN:SI:doc-YHPBCI2Y</dc:identifier><dc:language>sl</dc:language><dc:publisher xml:lang="sl">Slovensko farmacevtsko društvo</dc:publisher><dcterms:isPartOf xml:lang="sl">Farmacevtski vestnik</dcterms:isPartOf><dc:subject xml:lang="sl">farmacevtske oblike</dc:subject><dc:subject xml:lang="sl">kompleksi</dc:subject><dc:subject xml:lang="sl">lastnosti</dc:subject><dc:subject xml:lang="sl">polimeri</dc:subject><dcterms:temporal rdf:resource="2005-2025" /><dc:title xml:lang="sl">Interpolimerni kompleksi|</dc:title><dc:description xml:lang="sl">The developement of new pharmaceutical excipients is proceeding simultaneouslywith developement of new active pharmaceutical ingredients. The purpose of the developement of new pharmaceutical excipients is to achieve desirable properties in dosage forms like controlled release, improved bioavailabilty, enhanced stability etc. An example of new excipients are interpolymer complexes (IPC), which can obtain completely different propertiescompared to separate original polymers. The developement and properties of IPC are essentially influenced by manufacturing parameters. In this article we also present some experimental cases of the usage of IPC in pharmaceutical technology beside important manufacturing parameters. The feasibilities of the usage of computer models for developement of optimal conditions for IPC assembly are also pointed out. We can conclude that the research of influence and applications of IPC on formulation of dosage forms are nowadays the topic of great interest in pharmaceutical techology</dc:description><dc:description xml:lang="sl">Razvoj novih pomožnih snovi poteka sočasno z razvojem novih učinkovin. Namen razvoja novih pomožnih snovi je doseganje želenih lastnosti farmacevtskih oblik, kot so: nadzorovano sproščanje, izboljšanje biološke uporabnosti, poveoeana stabilnost idr. Primer novih pomožnih snovi so interpolimerni kompleksi (IPC), ki lahko izkazujejo povsem drugačne lastnosti od posameznih izhodiščnih polimerov. Na nastanek in lastnosti IPC imajo ključen vpliv parametri izdelave. V članku poleg ključnih parametrov izdelave obravnavamo tudi nekaj konkretnih primerov uporabe IPC v farmacevtski tehnologiji. Nakazane so tudi možnosti uporabe računalniških modelov za načrtovanje optimalnih pogojev za nastanek IPC. Zaključimo lahko,da so raziskave vpliva in uporabnosti IPC pri oblikovanju farmacevtskih oblik danes v farmacevtski tehnologiji zelo aktualne</dc:description><edm:type>TEXT</edm:type><dc:type xml:lang="sl">znanstveno časopisje</dc:type><dc:type xml:lang="en">journals</dc:type><dc:type rdf:resource="http://www.wikidata.org/entity/Q361785" /></edm:ProvidedCHO><ore:Aggregation rdf:about="http://www.dlib.si/?URN=URN:NBN:SI:doc-YHPBCI2Y"><edm:aggregatedCHO rdf:resource="URN:NBN:SI:doc-YHPBCI2Y" /><edm:isShownBy rdf:resource="http://www.dlib.si/stream/URN:NBN:SI:doc-YHPBCI2Y/5c0a31fe-1e17-4a0a-961d-8c8691f50257/PDF" /><edm:rights rdf:resource="http://rightsstatements.org/vocab/InC/1.0/" /><edm:provider>Slovenian National E-content Aggregator</edm:provider><edm:intermediateProvider xml:lang="en">National and University Library of Slovenia</edm:intermediateProvider><edm:dataProvider xml:lang="sl">Slovensko farmacevtsko društvo</edm:dataProvider><edm:object rdf:resource="http://www.dlib.si/streamdb/URN:NBN:SI:doc-YHPBCI2Y/maxi/edm" /><edm:isShownAt rdf:resource="http://www.dlib.si/details/URN:NBN:SI:doc-YHPBCI2Y" /></ore:Aggregation></rdf:RDF>